Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Jardiance (empagliflozin) and Synjardy (empagliflozin / metformin) are both medications used to treat Type 2 diabetes and lower the risk of heart problems in adults with this condition. They both contain empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which helps lower blood sugar by causing your body to get rid of excess sugar through urine. However, Synjardy also includes metformin, a biguanide that lowers the amount of sugar your liver makes and helps your body use insulin better. Jardiance is taken once daily, while Synjardy can be taken once or twice daily, depending on the formulation. Jardiance is available only as a brand-name medication. Synjardy is also only available as a brand-name medication and comes in both immediate-release and extended-release forms. Common side effects of both medications include urinary tract infections, yeast infections, and increased urination, but Synjardy can also cause diarrhea and nausea due to the metformin component. Additionally, Synjardy has a risk of lactic acidosis, a serious condition related to metformin, which Jardiance does not have. Both medications can interact with other diabetes medications, potentially causing low blood sugar.
Synjardy is a tablet containing empagliflozin (an SGLT2 inhibitor) and metformin (a biguanide). It helps lower blood sugar in people with Type 2 diabetes when used with a balanced diet and regular exercise. Synjardy can also help lower the risk of serious problems in adults with Type 2 diabetes who have heart disease, heart failure, or chronic kidney disease (CKD). Immediate-release tablets (IR) are for people 10 years and older and are taken twice a day. The extended-release tablets (XR) are only for adults and are taken once a day. Side effects include urinary tract infections and genital yeast infections.
Indications of Jardiance vs. Synjardy
Indications for
•Type 2 diabetes (in addition to diet and exercise) in people age 10 years and older
•Lowering the risk of death due to heart problems in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in adults with heart failure
•Lowering the risk of worsening kidney problems, hospitalization, and death due to heart problems in adults with chronic kidney disease (CKD)
•Lowering the risk of death due to heart problems in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in adults with Type 2 diabetes and heart failure
•Lowering the risk of worsening kidney problems, hospitalization, and death due to heart problems in adults with Type 2 diabetes and chronic kidney disease (CKD)